
TABLE OF CONTENTS

Sr. No.	Titles	Page No.
1	<i>Table of contents</i>	<i>i</i>
2	<i>List of Materials</i>	<i>vi</i>
3	<i>List of Instruments</i>	<i>viii</i>
4	<i>List of Abbreviations</i>	<i>ix</i>
5	<i>List of Figures</i>	<i>xi</i>
6	<i>List of Tables</i>	<i>xvi</i>
Chapter 1: Introduction		
1.1	Introduction	1
1.2	Objective of the research work	8
1.3	Rationale	8
1.4	Hypothesis	8
1.5	Research Plan	9
1.6	References	10
Chapter 2: Literature Review		
2.1	Introduction	13
2.2	Asthma	13
2.2.1	Airway inflammation in asthma	13
2.2.2	Inflammatory Cells in Asthmatic Airways	14
2.2.3	Inflammatory Mediators Involved in Asthma	14
2.3	Chronic Obstructive Pulmonary Disease (COPD)	15
2.3.1	Inflammatory Cells in COPD	16
2.3.2	Inflammatory Mediators Involved in COPD	16
2.3.3	Airflow Limitation	16
2.4	Current Medications	17
2.5	Neurotrophins in lung diseases	19
2.5.1	Basis of BDNF expression and signalling	19
2.5.2	BDNF in the lung	20
2.5.3	BDNF and Pulmonary inflammatory conditions	21
2.5.4	BDNF as a potential target for treatment of asthma and COPD	22

2.6	Neurotrophins in inflammatory conditions	22
2.6.1	Neurogenic inflammation by neurotrophins	22
2.6.2	Amplification of the allergic immune response	22
2.6.3	Angiogenesis and microvascular remodelling	23
2.7	Gene/siRNA delivery in pulmonary diseases	23
2.8	Basic of RNA interference	24
2.9	Other potential targets for pulmonary gene delivery	25
2.10	Non viral vectors based gene delivery	27
2.11	Pulmonary delivery platforms	31
2.11.1	Metered dose inhalers (MDI)	31
2.11.2	Dry Powder Inhaler	31
2.11.3	Nebulizers	32
2.12	Cationic polymers based non viral vectors	34
2.12.1	Polyethylenimine	34
2.12.2	Chitosan	38
2.13	References	43
Chapter 3: siRNA profiling and Analytical Method Development		
3.1	siRNA Selection	57
3.2	siRNA Characterization	57
3.3	Analytical Method Development	58
3.3.1	Material and Instruments	58
3.3.2	UV Spectrophotometric Analysis of siRNA by Nanodrop (i)Quantification of siRNA Concentration (ii) Purity of siRNA (iii) Nanodrop spectrophotometer	58
3.4	Nuclease Free Water Preparation	60
3.5	Method verification	60
3.6	Gel Electrophoresis	61
3.7	Result and discussion	63
3.8	References	72
Chapter 4: Development of Chitosan based non viral vectors		

4.1	Introduction	73
4.2	Material and Methods	74
4.3	Preparation of Trimethylated Chitosan (TMC)	74
4.4	Determination of degree of Quarterisation	75
4.5	Solubility improvement determination	75
4.6	<i>In vitro</i> cytotoxicity assay (MTT Assay)	76
4.7	Conjugation of Heterocyclic moieties on TMC	77
4.8	Nuclear Magnetic Resonance spectroscopy (NMR) Analysis	78
4.9	Fourier Transformed Infrared Spectroscopy (FTIR) Analysis	78
4.10	2, 4, 6- Trinitrobenzene 1-Sulphonic acid (TNBS) assay	79
4.11	Buffering Capacity/Acid Base titration	79
4.12	Haemolysis Study	80
4.13	Erythrocytes aggregation	80
4.14	<i>In vitro</i> cytotoxicity assay (MTT Assay)	81
4.15	Result and Discussion	81
4.16	References	99
Chapter 5: Development of Polyethylenimine based non viral vectors		
5.1	Introduction	102
5.2	Conjugation of Urocanic acid on PEI	103
5.3	Nuclear Magnetic Resonance spectroscopy (NMR) Analysis	104
5.4	Fourier Transformed Infrared Spectroscopy (FTIR) Analysis	104
5.5	2, 4, 6- Trinitrobenzene 1-Sulphonic acid (TNBS) assay	104
5.6	Buffer Capacity	105
5.7	Haemolysis Study	105
5.8	Erythrocytes aggregation	105
5.9	<i>In vitro</i> cytotoxicity assay (MTT Assay)	106

5.10	Result and Discussion	107
5.11	References	116
Chapter 6: Formulation Development and Characterization		
6.1	Polyplex Preparation	118
6.2	Agarose Gel retardation assay (Gel Electrophoresis)	118
6.3	Complexation efficiency	118
6.4	siRNA Integrity determination	119
6.5	Polyplex Size and zeta Potential Analysis	119
6.6	<i>In vitro</i> Cell line Studies	119
6.6.1	Introduction	119
6.6.2	Cell Line Cultures	121
6.6.3	Cell Culturing Protocol	121
6.6.4	Cell Counting using Haemocytometer	122
6.6.5	<i>In vitro</i> cytotoxicity assay	123
6.6.6	Cell Uptake studies (i) Confocal microscopy (ii) Flow Cytometry (FACS Analysis)	124
6.7	Electrolyte induced aggregation	127
6.8	Heparin Polyanion Competition Assay	128
6.9	Serum stability study	129
6.10	Stability in bronchoalveolar lavage Fluid (BALF)	130
6.11	Transmission electron microscopy (TEM)	130
6.12	Result and Discussion	130
6.10	References	165
Chapter 7: Nebulized siRNA delivery and Characterization		
7.1	Introduction	167
7.2	<i>In vitro</i> aerosolization of formulations by Twin Stage Impinger	169
7.3	Stability of the formulations post Nebulization	170
7.3.1	siRNA Integrity	170
7.3.2	Cell Uptake	171
7.3.3	Particle size and zeta potential	171

7.4	Result and Discussion	171
7.5	References	178
Chapter 8: Animal studies		
8.1	Introduction	180
8.2	Methods	180
8.3	Housing and Feeding Conditions	180
8.4	Preparation of Animals	180
8.5	Efficacy study	181
8.5.1	Ovalbumin (OVA) Challenged inflammatory model	181
8.6	Gene knockdown efficiency by RT-PCR	181
8.6.1	Primers selection	183
8.6.2	Total RNA isolation	183
8.6.3	RNA to cDNA conversion	185
8.6.4	Real Time PCR	186
8.7	Bronchoalveolar lavage fluid (BALF) examination	187
8.8	Histopathological examination of lung	187
8.9	Statistical analysis	188
8.10	Result and discussion	188
8.11	References	193
Chapter 9: Summary and Conclusion		
9.1	Summary and conclusion	195-210